Walleye Capital’s NextCure NXTC Stock Holding History

Walleye Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,771	Closed	-$29.1K	–	5335
2024 Q3	$29.1K	Hold	1,771	–	–	﹤0.01%	4745
2024 Q2	$33.8K	Buy	+1,771	New	+$34.4K	﹤0.01%	5025

Other funds holding NXTC

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's NXTC Position: Q4 2024 in Review

Walleye Capital sold out of NextCure (NXTC) in Q4 2024, closing a stake of 1,771 shares — an estimated $29.1K sold.

Walleye Capital first reported a position in NXTC in Q2 2024 and held it in 2 quarters. The position peaked at $33.8K in Q2 2024. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2024.

Walleye Capital reported no remaining NextCure position as of Q4 2024 after selling out during the quarter.
Walleye Capital sold 1,771 NextCure shares in Q4 2024, an estimated $29.1K.
Walleye Capital first reported a position in NextCure in Q2 2024 and held it in 2 quarters.
Walleye Capital's NextCure position peaked at $33.8K in Q2 2024.
45 funds tracked by Wall St. Rank held NextCure as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.